Get startedLog in
    Picture of Pfizer logo

    PFE — Pfizer News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareConservativeLarge CapSuper Stock
    All News

    Brief: Pfizer Says Vesper-1 Shows Nearly 16% Weight Loss At 32 Weeks On 2.4 Mg Weekly Berobenatide

    Picture of Pfizer logoPfizer
    06/06/2026 14:04
    BRIEF-Pfizer Says Vesper-1 Shows Nearly 16% Weight Loss At 32 Weeks On 2.4 Mg Weekly Berobenatide
    June 6 (Reuters) - Pfizer Inc PFE.N:
    • ROBUST PHASE 2B EFFICACY AND FAVORABLE TOLERABILITY SUPPORT MONTHLY DOSING FOR PFIZER’S GLP-1 RA BEROBENATIDE
    • PFIZER - VESPER-1 SHOWS NEARLY 16% WEIGHT LOSS AT 32 WEEKS ON 2.4 MG WEEKLY BEROBENATIDE
    • PFIZER - PLANS 10 PHASE 3 BEROBENATIDE STUDIES IN 2026 AS PART OF 20+ OBESITY TRIALS
    Source text: ID:nBw37zF6pa
    Further company coverage: PFE.N

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Pfizer

    See all news